US 10385031
Substituted piperazines as selective HDAC1,2 inhibitors
granted A61PA61P35/00A61P35/02
Quick answer
US patent 10385031 (Substituted piperazines as selective HDAC1,2 inhibitors) held by Regenacy Pharmaceuticals, Inc. expires Mon Aug 15 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Regenacy Pharmaceuticals, Inc.
- Grant date
- Tue Aug 20 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 15 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61P, A61P35/00, A61P35/02, A61P7/00